Proton beam therapy potentially improves quality of life (QOL) by sparing more healthy brain tissue than photon radiotherapy. With improved targeting and the dosimetric advantages of proton beam therapy, we aimed to test whether hypofractionated proton beam therapy could improve survival and QOL in older patients with glioblastoma.

2024年12月1日 · We found that short-course, dose-escalated proton beam therapy, with treatment based on 18 F-DOPA PET and MRI findings, can be delivered safely and with good outcomes in terms of overall survival and quality of life.

2024年12月1日 · Hypofractionated proton beam therapy for 1–2 weeks, guided by 18 F-DOPA PET and MRI, is a safe, convenient, and active treatment option for older patients with glioblastoma.

Hypofractionated proton beam therapy for 1–2 weeks, guided by 18F-DOPA PET and MRI, is a safe, convenient, and active treatment option for older patients with glioblastoma.

2023年5月31日 · Proton beam therapy (PBT) can spare more healthy tissue that may improve quality of life for this patient population. With improved targeting of disease along with dosimetric advantages of PBT, this phase II trial tested whether hypofractionated PBT can offer both improved survival and quality of life.

Proton beam therapy potentially improves quality of life (QOL) by sparing more healthy brain tissue than photon radiotherapy. With improved targeting and the dosimetric advantages of proton beam therapy, we aimed to test whether hypofractionated proton beam therapy could improve survival and QOL in older patients with glioblastoma.

Updated results from a phase II study of mini-hyper-CVD (mini-HCVD) plus inotuzumab ozogamicin (INO), with or without blinatumomab (Blina), in older adults with newly diagnosed Philadelphia chromosome (Ph)-negative B-cell acute lymphoblastic leukemia (ALL).

Short-course hypofractionated proton beam therapy, incorporating 18F-DOPA PET and contrast-enhanced MRI targeting, for patients aged 65 years and older with newly diagnosed glioblastoma: a single-arm phase 2 trial.

Phase II trial of bevacizumab and temozolomide for treatment of elderly patients with newly diagnosed glioblastoma. Bortezomib sensitization of recurrent glioblastoma with unmethylated MGMT promoter to temozolomide, a phase II study (NCT03643549).

2024年11月20日 · The following is a summary of “Short-course hypofractionated proton beam therapy, incorporating 18F-DOPA PET and contrast-enhanced MRI targeting, for patients aged 65 years and older with newly diagnosed glioblastoma: a single-arm phase 2 trial,” published in the November 2024 issue of Oncology by Vora et al.